U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07671417) titled 'Imaging Study of a CAIX Binder in Metastatic Clear Cell RCC.' on June 22.

Brief Summary: This imaging study aims to assess the feasibility, biodistribution, and dosimetry of a novel Carbonic Anhydrase IX (CAIX) Binder in Subjects with Metastatic Clear Cell Renal Cell Cancer (RCC).

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Metastatic Clear Cell Renal Cell Carcinoma

Intervention: DIAGNOSTIC_TEST: RYZ512

Imaging Agent

Recruitment Status: NOT_YET_RECRUITING

Sponsor: RayzeBio, Inc.

Disclaimer: Curated by HT Syndication....